Back to Search

A Phase 2 Trial of the Combination of Polatuzumab Vedotin, Venetoclax and Rituximab and Hyaluronidase Human for Relapsed and Refractory Mantle Cell Lymphoma


  • Protocol Number: 202109063
  • Principal Investigator: Kahl, Brad
  • Cancer Types: Lymphoma

For more information on this trial, contact us here:

Phone
800-600-3606
Email
info@ccadmin.wustl.edu

Brief Summary

Protocol Interventions